{"id":"W2547680646","doi":"10.1093/annonc/mdw435.39","title":"NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Ipilimumab; Response Evaluation Criteria in Solid Tumors; Oncology; Docetaxel; Progression-free survival; Phases of clinical research; Chemotherapy; Adverse effect; Randomization; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00131843,0.0004449995,0.001665525,0.0003073129,0.00007493165,0.00001096671,0.0002911854,0.0002760653,0.0002386197],"category_scores_gemma":[0.0005713183,0.0003095716,0.0006484712,0.0003863643,0.0006998622,0.0001264323,0.00002776828,0.0001667247,0.000002594097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001256301,"about_ca_system_score_gemma":0.001666943,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004844208,"about_ca_topic_score_gemma":0.0001249093,"domain_scores_codex":[0.9967348,0.0002228089,0.001448589,0.0005220052,0.000474265,0.0005975149],"domain_scores_gemma":[0.9956117,0.001286265,0.001510662,0.0005385031,0.0007656205,0.0002872267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.5385947,0.006134148,0.0003101694,0.0004218225,0.001667391,0.00001239851,0.000819108,0.00000154202,0.1810677,0.00008656362,0.001838541,0.2690459],"study_design_scores_gemma":[0.3154622,0.07723813,0.0007111248,0.0006523921,0.0002095328,0.000007618367,0.0000652328,0.00008208126,0.5456101,0.0001940224,0.05950025,0.0002673716],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787294,0.001621113,0.0007979185,0.01261953,0.0003572838,0.004881341,0.000678806,0.00004629673,0.0002683674],"genre_scores_gemma":[0.9917064,0.002149235,0.001683659,0.003040286,0.0002598395,0.000615519,0.000146552,0.00008237908,0.0003160892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3645423,"threshold_uncertainty_score":0.9999356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1281038229884469,"score_gpt":0.4189531583647975,"score_spread":0.2908493353763506,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}